RBPMS: A Potential Drug Target for Heart Disease (G11030)

Target Name: RBPMS

NCBI ID: G11030

RBPMS

RBPMS: A Potential Drug Target for Heart Disease

RBPMS (Ribonucleotide-conjugated Proteins), also known as Heart and RRM-expressed Sequence, is a molecule that has been identified as a potential drug target or biomarker for various diseases, including heart disease and cancer.

Heart disease is a leading cause of death worldwide, and its incidence is expected to increase in the coming years due to the increasing number of cases of obesity, diabetes, and other lifestyle-related factors. Therefore, identifying potential drug targets or biomarkers for heart disease is of great importance. RBPMS is one of the promising candidates for this purpose.

RBPMS is a protein that is expressed in the heart and root meristem, which is a critical region of the plant that develops into new shoots and roots. It is composed of a core RNA molecule that is surrounded by a protein shell. The core RNA molecule contains 4'-end overhangs that are compatible with the interaction of with DNA-binding proteins, which is expected to play a role in the regulation of gene expression.

RRM (Randomly Oriented Marker) is a repetitive DNA sequence that is located at the 5' end of the RNA molecule. It is known to be involved in the regulation of gene expression and has been implicated in various cellular processes, including cell growth, apoptosis, and DNA replication. Therefore, the expression of RBPMS and its associated DNA-binding proteins may be regulated by theRRM sequence.

Several studies have demonstrated that RBPMS is involved in various cellular processes that are related to heart disease, including cell proliferation, apoptosis, and fibrosis. For example, studies have shown that RBPMS is involved in the regulation of cell proliferation and apoptosis, which are critical processes that can contribute to the development of heart disease.

In addition, studies have also shown that RBPMS is involved in the regulation of fibrosis, which is a process that can lead to the development of scar tissue in the heart. Fibrosis is a condition that can be caused by various factors, including mechanical stress, inflammation, and infection. Therefore, identifying RBPMS as a potential drug target or biomarker for heart disease may be of great interest.

RRM is also known to be involved in the regulation of gene expression and has been shown to play a role in the regulation of various cellular processes. Therefore, the expression of RBPMS and its associated DNA-binding proteins may be regulated by theRRM sequence.

In conclusion, RBPMS is a molecule that has been identified as a potential drug target or biomarker for various diseases, including heart disease and cancer. Its expression and associated proteins may be regulated by theRRM sequence, which is known to play a role in the regulation of gene expression and various cellular processes. Further studies are needed to determine the role of RBPMS in the development and progression of heart disease.

Protein Name: RNA Binding Protein, MRNA Processing Factor

Functions: Acts as a coactivator of transcriptional activity. Required to increase TGFB1/Smad-mediated transactivation. Acts through SMAD2, SMAD3 and SMAD4 to increase transcriptional activity. Increases phosphorylation of SMAD2 and SMAD3 on their C-terminal SSXS motif, possibly through recruitment of TGFBR1. Promotes the nuclear accumulation of SMAD2, SMAD3 and SMAD4 proteins (PubMed:26347403). Binds to poly(A) RNA (PubMed:17099224, PubMed:26347403)

The "RBPMS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBPMS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets